会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 52. 发明公开
    • 새로운 이소티아졸 세펨 화합물 및 그 제조방법
    • 异黄酮CEPHEM衍生物及其制备方法
    • KR1020010084201A
    • 2001-09-06
    • KR1020000009063
    • 2000-02-24
    • 한국과학기술연구원
    • 고훈영최경일조용서배애님차주환김보형
    • C07D501/16
    • Y02P20/55
    • PURPOSE: Provided is an isothiazol cephem derivative which has broad range of antimicrobial activity. And its producing method is also provided. CONSTITUTION: The cephalosporin compound represented by formula (1) and its pharmaceutically acceptable salts are produced. In the formula, R1 is hydrogen or an amine protecting group generally used in cephalosporin compound; R2 is hydrogen or an oxim protecting group; R3 is hydrogen or a chloro group; R5 is hydrogen or an ester producing group, a salt producing atom or a carboxy protecting group; and R4 is ring substituent having Q group, in which Q is hydrogen, halogen, hydroxy, mercapto, cyano, carboxy, carboxylic acid ester, carbamoyloxymethyl, N,N-dimethylcarbamoyloxymethyl, carbamoyl, N,N-dimethylcarbamoyl, C1 to C4 alkyl, C1 to C4 alkyloxy, halogen substituted methyl, halogen substituted C1 to C4 alkyloxy, aryl or hetero ring substituent. The cephalosporin derivative of the formula (1) is produced by reacting a compound of formula (7) with a compound of formula (8).
    • 目的:提供具有广泛抗菌活性的异噻唑头孢烯衍生物。 并提供其生产方法。 构成:制备由式(1)表示的头孢菌素化合物及其药学上可接受的盐。 在该式中,R 1是氢或通常用于头孢菌素化合物中的胺保护基; R2是氢或肟基保护基; R3是氢或氯基; R5是氢或产酯基,产盐原子或羧基保护基; R4是具有Q基团的环取代基,其中Q是氢,卤素,羟基,巯基,氰基,羧基,羧酸酯,氨基甲酰氧基甲基,N,N-二甲基氨基甲酰氧基甲基,氨基甲酰基,N,N-二甲基氨基甲酰基, C1至C4烷氧基,卤素取代的甲基,卤素取代的C1至C4烷氧基,芳基或杂环取代基。 式(1)的头孢菌素衍生物通过使式(7)的化合物与式(8)的化合物反应来制备。
    • 54. 发明公开
    • 세펨 에스테르 화합물 및 이의 제조방법
    • CEPHEM ESTER化合物及其制备方法
    • KR1020000007667A
    • 2000-02-07
    • KR1019980027115
    • 1998-07-06
    • 한국과학기술연구원
    • 고훈영장문호김유승최경일조용서배애님차주환심상철
    • C07D501/24C07D501/20
    • PURPOSE: A cephem compound for an oral administration having a broad spectrum antibacterial activity is prepared by esterifying cephalosporin compound in the presence of solvent. CONSTITUTION: The compound(I) is manufactured by reacting cephalosporin compound(Korea patent application No.1997-36921) and halide compound in the presence of solvent such as acetone, acetonitrile, dioxane, N,N-dimethylformamide, dimethylsulfoxide at -10 to 25°C for 10 min-12hr(preferably at 0 to 5°C for 10 min-1 hr). In formula(I), R1 = H or trityl, R2 = H, trityl, methyl or cyclopentyl; R3 = H, chloro, bromo or methoxy; R4 = acethoxyethyl, pyvaloyloxymethyl or isopropoxycarbonyloxymethyl. It shows a broad spectrum antibacterial activity about a staphylococcus aureus containing gram-positive bacterium and a gram-positive bacterium, especially methicillin-resistant staphylococcus aureus.
    • 目的:通过在溶剂存在下酯化头孢菌素化合物来制备具有广谱抗菌活性的口服给药的头孢烯化合物。 构成:化合物(I)通过在-10℃下在溶剂如丙酮,乙腈,二恶烷,N,N-二甲基甲酰胺,二甲亚砜等溶剂存在下使头孢菌素化合物(韩国专利申请No.1997-36921)与卤化物反应制造而成 25℃10分钟-12小时(优选0-5℃10分钟-1小时)。 在式(I)中,R 1 = H或三苯甲基,R 2 = H,三苯甲基,甲基或环戊基; R3 = H,氯,溴或甲氧基; R4 =乙氧基乙基,吡喃酰氧基甲基或异丙氧羰基氧基甲基。 它显示了对含有革兰氏阳性菌和革兰氏阳性菌,特别是耐甲氧西林金黄色葡萄球菌的金黄色葡萄球菌的广谱抗菌活性。